MAdCAM-1 Overview
Molecule Name
Mucosal addressin cell adhesion molecule-1
Synonyms
MAdCAM-1,MAdCAM1,Mucosal vascular addressin cell adhesion molecule 1 transcript variant 1
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs1
Highest Development StageApproved
Target Synonym
Mucosal addressin cell adhesion molecule 1，MADCAM1，hMAdCAM-1，Mucosal Vascular Addressin Cell Adhesion Molecule 1，MACAM1，MAdCAM-1，Mucosal Addressin Cell Adhesion Molecule-1
Background
The mucosal addressin cell adhesion molecule-1 (MAdCAM-1) takes a key role in the endothelial adhesion and migration of lymphocytes to sites of inflammation in inflammatory disease. In vitro and in vivo data indicate that blockade of the adhesion molecule mucosal address in cell adhesion molecule (MAdCAM) pathway decreases leukocyte homing to the gut by inhibiting the interaction between MAdCAM and its ligand the α4β7 integrin expressed on lymphocytes.
MAdCAM-1 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ontamalimab | SHP-647; PF-00547659; PF-547659 | Phase 3 Clinical | Pfizer Inc | Colitis, Ulcerative; Crohn Disease; Fatty Liver; Ileitis | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Colitis, Ulcerative; Crohn Disease; Pouchitis | Details |
| Vedolizumab Biosimilar (Intas Pharmaceuticals) | INTP-53; INTP53 | Phase 3 Clinical | Intas Pharmaceuticals Ltd | Colitis, Ulcerative | Details |
| Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 1 Clinical | Alvotech Swiss Ag | Colitis, Ulcerative; Immune System Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Carcinoma, Non-Small-Cell Lung; Celiac Disease; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Crohn Disease; Gastritis; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Inflammatory Bowel Diseases; Melanoma; Neoplasms; Pediatric Crohn's disease; Pediatric ulcerative colitis; Pouchitis; Solid tumours; Urogenital Neoplasms | Details |